The executive team behind the Itero start-up says that high-tech companies can teach biotech a thing or two about more efficient drug development. Specifically, signing up partnership agreements with companies halfway around the world can help move product work, especially when you're out to penetrate the world of biosimilars. There's a lot that Itero won't discuss at this stage, but development strategy is taking center stage. Article